Dec. 23, 2019: U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Allergan’s UBRELVY™ (ubrogepant) for the acute treatment of migraine with or without aura in adults.
UBRELVY™ is the first and only orally-administered, highly potent calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start.
Migraine is a neurological disease that is characterized by intermittent migraine attacks with symptoms that are often incapacitating.
Migraine afflicts 31 million Americans and is the thirds general disease and second leading cause of disability worldwide. It provided lasting relief up to 24 hours as well.
UBRELVY™(50 mg,100 mg), block CGRP, a protein that is released during a migraine attack, from binding to its receptors, without constricting blood vessels, which some older treatments are known to do. https://www.allergan.com/News/Details/2019/12/Allergan%20Receives%20US%20FDA%20Approval%20for%20UBRELVY%20for%20the%20Acute%20Treatment%20of%20Migraine%20with%20or%20without%20Au